A Journey back in time to the origin of stem cells

Proteins that regulate animal stem cells are much older than animals themselves

20-Nov-2024 - A new study published in Nature Communications reveals that critical proteins involved in animal stem cell regulation are much older than previously thought, predating the origin of animals that likely evolved more than 700 million years ago. The international research team included scientists ...

Protein interactions: who is partying with whom and who is ruining the party?

New method for investigating protein interaction networks - also of interest for pharmaceutical research

18-Oct-2024 - Inside cells, it's like in a packed dance club: hundreds are partying. Some keep to themselves, others make their way through the crowd, chatting to everyone they meet. Some just say a quick hello, others stay with their best friends. In this club, there are all kinds of different interactions ...

Synthetic chemistry approach yields new compounds with potential biomedical applications

The study marks a significant advancement in chemical synthesis techniques, leveraging modern organic chemistry and engineered enzymes

10-May-2024 - Researchers at Rice University have successfully synthesized a group of natural compounds known as fusicoccanes. The molecules, found in various living organisms, exhibit diverse biological activities, including the ability to modulate protein-protein interactions within biological systems. The ...

A new approach to recording cellular activities

Potential for accelerating research: A novel chemical labeling method allows transient events in cells to be recorded for later analysis

27-Feb-2024 - In living cells, a vast number of transient events occur simultaneously, each of them important for a given cell in carrying out its function. The faithful recording of these transient activities is a prerequisite for a molecular understanding of life, yet obtaining such recordings is extremely ...

Oral peptides: A new era in drug development

The research opens the door to a new class of orally available drugs, addressing a long-standing challenge in the pharmaceutical industry

10-Jan-2024 - For decades, a substantial number of proteins, vital for treating various diseases, have remained elusive to oral drug therapy. Traditional small molecules often struggle to bind to proteins with flat surfaces or require specificity for particular protein homologs. Typically, larger biologics ...

RIANA Therapeutics enters into collaboration agreement with LDC

"This cooperation has the great potential to lay the groundwork for new, urgently needed therapeutic approaches for AML patients"

13-Sep-2023 - RIANA Therapeutics, a spin-off from Vetmeduni Vienna has entered into a collaborative agreement with the Lead Discovery Center GmbH, a renowned organization specialized in translational drug discovery. This partnership marks the first important milestone on RIANA Therapeutics´ mission to discover ...

How the coronavirus SARS-CoV-2 communicates with human cells

Landscape of molecular contacts

12-Oct-2022 - What exactly are the molecular interactions between the virus causing COVID-19 and its human host? How might our genetic differences cause different disease courses? And how do still-emerging virus variants differ in their host-virus interactions? To get to the bottom of these questions, an ...

Analyze proteins and protein interactions with hitherto unseen performance

Life-science startup Actome announces release of first commercial products

09-May-2022 - Actome has released the first commercial products to the EU market based on the Protein Interaction Coupling (PICO) Technology. The PICO assay kits for measuring proteins and protein interactions are available throughActome's online webshop. Actome GmbH is a life-science startup form Freiburg ...

Life-science start-up Actome and QIAGEN announce commercial partnership

Licensing and co-marketing agreement signed

11-Jan-2022 - Actome GmbH, a life-science start-up company from the University of Freiburg and Hahn-Schickard, Germany has signed a license agreement and a co-marketing agreement with QIAGEN GmbH, Hilden, Germany, to jointly accelerate the market entry of Actome’s Protein-Interaction-Coupling (PICO) ...

Bayer and X-Chem Expand Drug Discovery Collaboration to Discover Novel Medicines

14-Jul-2016 - Bayer and X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, have entered into an expanded global drug discovery collaboration across multiple therapeutic areas and target ...